Pneumococcal vaccine associated with 50 percent lower risk of heart attacks

Oct 07, 2008

Pneumococcal (pneumonia) vaccination was associated with a 50% lower risk of heart attacks 2 years after vaccination, suggests a large hospital-based case-control study published in CMAJ.

In a population of patients at high risk of heart attack, the study compared the rates of pneumococcal vaccine between patients having a heart attack and patients without such an event.

"After a number of confounding and modifying variables were taken into account, the odds of having received a vaccination against S. pneumonia in the group who had experienced myocardial infarction was about half that in the control group," write Dr. Danielle Pilon and coauthors from the University of Sherbrooke and McMaster University. "Moreover, this association appeared stronger and the benefit appeared to increase with time since exposure to the vaccine."

In a related commentary, Dr. Mohammad Madjid from the Texas Heart Institute hypothesizes that the pneumonia vaccine protects against heart attacks because it prevents pneumonia which has been shown to trigger heart attacks. Other studies suggest that respiratory (especially influenza) and urinary tract infections are associated with heart attacks. He suggests that physicians should focus on increasing vaccination rates against pneumonia and influenza in high risk patients as rates in the US and other countries are well below target goals.

On the web:

www.cmaj.ca/press/pg773.pdf
www.cmaj.ca/press/pg749.pdf

Source: Canadian Medical Association Journal

Explore further: Medical charity accuses US of pushing India to ease patent rules

add to favorites email to friend print save as pdf

Related Stories

Victim of chimp attack gets a full face transplant

Jun 10, 2011

(AP) -- A Connecticut woman mauled by a chimpanzee gone berserk has received a new face in the third such operation performed in the U.S. and is looking forward to going out in public again and eating hot ...

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
not rated yet Oct 07, 2008
is this real or a push by the manufacturer to sell vaccine? sorry to say but we need more independent studies.